logo
Plus   Neg
Share
Email

Gilead: Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta

Biopharmaceutical company Gilead Sciences Inc. (GILD) announced Sunday that its unit Kite revealed long-term follow-up data from the pivotal ZUMA-1 study of Yescarta (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma.

Yescarta is the first chimeric antigen receptor T or CAR T cell therapy to be approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma or DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Yescarta is not indicated for patients with primary central nervous system lymphoma.

Kite, focused on chimeric antigen receptor and T cell receptor engineered cell therapies, noted that with a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission.

Detailed results were presented at the Annual Meeting of the American Society of Hematology in Atlanta and published in The New England Journal of Medicine.

Sattva Neelapu, ZUMA-1 Co-Lead Investigator, said, "As observed in the SCHOLAR-1 study, treatment options for patients with refractory large B-cell lymphoma have yielded a median overall survival of just six months, with fewer than ten percent of patients achieving complete remission. The durability of response seen with Yescarta in this long-term follow-up reinforces the major advance that CAR T therapy represents for these patients."

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
McDonald's Corp. has announced the return of its popular Shamrock Shake milkshake for a limited time at participating U.S. restaurants nationwide. The minty green milkshake is made with McDonald's vanilla soft serve blended with Shamrock Shake syrup and topped with whipped topping. It first debuted on the McDonald's menu in 1970 and has been a seasonal tradition for nearly 50 years. Asia-focused lender HSBC, through its blockchain-powered platform, has reduced the cost of settling foreign exchange trades by 25 percent, Reuters reported quoting a bank executive overseeing the project. Mark Williamson, chief operating officer of FX cash trading and risk management, told that the bank processes between 3,500 and 5,000 trades a day on its "FX Everywhere" system. PepsiCo, Inc. (PEP) reported fourth-quarter core EPS of $1.49 compared to $1.31, prior year. Excluding the impact of foreign exchange translation, core constant currency EPS increased 17 percent year-over-year. On average, 19 analysts polled by Thomson Reuters expected the company to report profit per...
Follow RTT